An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
The partners also aim to expand their work to Latin America for the first time
Tembo and UFlex-Asepto have co-developed 100% renewable and recyclable paper straw solution that will be food grade, moisture-resistant and made from sustainably sourced papers
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
The first wave of shipments includes several countries, such as Germany, France and Austria
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Subscribe To Our Newsletter & Stay Updated
